Share the post "Eris Lifesciences : Q4 2024 Financial Quarterly Report : YoY Sales Up 36.77 %, QoQ Up 13.29 %"
Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 36.77 % in the past year, substantial increase in net sales/revenue by 13.29 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 1400 %. Marginal increase in other income during this quarter, up by 260.71%.
- Profit over the Year and quarter: Significant improvement in profitability for Eris Lifesciences Limited. Notable increase of 29.53 % in net profit Year to Year, Eris Lifesciences Limited’s profitability dropped by -21.51 % Quarter to Quarter.
- EPS over the Year and quarter: EPS increased by 8.52 % Year to Year. EPS decreased by -30.86 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 402.798 Cr | Rs. 486.297 Cr | Rs. 550.925 Cr | + 13.29 % | + 36.77 % |
| Expenses | Rs. 283.9 Cr | Rs. 310.79 Cr | Rs. 402.5 Cr | + 29.51 % | + 41.78 % |
| Operating Profit | Rs. 118.9 Cr | Rs. 175.51 Cr | Rs. 148.43 Cr | -15.43 % | + 24.84 % |
| OPM % | 29.52 % | 36.09 % | 26.94 % | -9.15 % | -2.58 % |
| Other Income | Rs. 1.01 Cr | Rs. 4.2 Cr | Rs. 15.15 Cr | + 260.71 % | + 1400 % |
| Interest | Rs. 8.87 Cr | Rs. 18.12 Cr | Rs. 33.03 Cr | + 82.28 % | + 272.38 % |
| Depreciation | Rs. 35.13 Cr | Rs. 45.72 Cr | Rs. 53.9 Cr | + 17.89 % | + 53.43 % |
| Profit before tax | Rs. 75.91 Cr | Rs. 115.87 Cr | Rs. 76.65 Cr | -33.85 % | + 0.97 % |
| Tax % | 19 % | 12.44 % | 3.9 % | -8.54 % | -15.1 % |
| Net Profit | Rs. 61.48 Cr | Rs. 101.46 Cr | Rs. 79.63 Cr | -21.52 % | + 29.52 % |
| EPS in Rs | Rs. 4.79 | Rs. 7.54 | Rs. 5.21 | -30.9 % | + 8.77 % |
Today, we’re looking at Eris Lifesciences Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 36.77 %. However, it did see a marginal increase of 13.29 % from the previous quarter. Expenses ticked up slightly by 29.51 % quarter-on-quarter, aligning with the annual rise of 41.78 %. Operating profit, while up 24.84 % compared to last year, faced a quarter-on-quarter dip of -15.43 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -2.58 %, but a shrinkage of -9.15 % sequentially. Other income rose by 260.71 % compared to the last quarter, despite an annual growth of 1400 %. Interest expenses surged remarkably by 82.28 % from the previous quarter, yet the year-over-year increase remains at a moderate 272.38 %. Depreciation costs climbed by 17.89 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 53.43 %. Profit before tax grew annually by 0.97 % but saw a reduction from the preceding quarter by -33.85 %.
Tax expenses as a percentage of profits decreased slightly by -15.1 % compared to last year, with a more notable quarter-on-quarter decrease of -8.54 %. Net profit rose by 29.52 % year-on-year but witnessed a -21.52 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 8.77 % but a quarterly fall of -30.9 %. In summary, Eris Lifesciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 402.798 Cr | Rs. 486.297 Cr | Rs. 550.925 Cr | + 13.29 % | + 36.77 % |
| Expenses | Rs. 283.9 Cr | Rs. 310.79 Cr | Rs. 402.5 Cr | + 29.51 % | + 41.78 % |
| Operating Profit | Rs. 118.9 Cr | Rs. 175.51 Cr | Rs. 148.43 Cr | -15.43 % | + 24.84 % |
| Net Profit | Rs. 61.48 Cr | Rs. 101.46 Cr | Rs. 79.63 Cr | -21.52 % | + 29.52 % |
| EPS in Rs | Rs. 4.79 | Rs. 7.54 | Rs. 5.21 | -30.9 % | + 8.77 % |
In reviewing Eris Lifesciences Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 36.77 % year-on-year growth, however, there was a minor increase of 13.29 % from the previous quarter. Expenses rose by 41.78 % compared to the previous year, with a 29.51 % increase quarter-on-quarter. Operating Profit surged by 24.84 % annually, and saw a -15.43 % decrease from the last quarter.
Net Profit showed yearly increase of 29.52 %, and experienced a -21.52 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 8.77 % annually, however dipped by -30.9 % compared to the last quarter. In essence, while Eris Lifesciences Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
